ABC | Volume 112, Nº3, Março 2019

Atualização Atualização da Diretriz em Cardiologia do Esporte e do Exercício da Sociedade Brasileira de Cardiologia e da Sociedade Brasileira de Medicina do Exercício e Esporte – 2019 Arq Bras Cardiol. 2019; 112(3):326-368 201. Li N, Wang Q, Sibrian-Vazquez M, Klipp RC, Reynolds JO, Word TA, et al. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. Int J Cardiol. 2017 Jan 15;227:668-73. 202. SumitomoN. Current topics in catecholaminergic polymorphic ventricular tachycardia. J Arrhythm. 2016;32(5):344-51. 203. Wall JJ, Iyer RV. Catecholaminergic polymorphic ventricular tachycardia. Pediatr Emerg Care. 2017;33(6):427-431. 204. Roston TM, Vinocur JM, Maginot KR, Mohammed S, Salerno JC, Etheridge SP, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 2015;8(3):633-42. 205. PrioriSG,NapolitanoC,MemmiM,ColombiB,DragoF,GaspariniM,etal. Clinical andmolecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69-74. 206. Imberti JF, Underwood K, Mazzanti A, Priori SG. Clinical challenges in catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ. 2016;25(8):777-83. 207. Liu N, Ruan Y, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis. 2008;51(1):23-30. 208. Xiong J, Liu X, Gong Y, Zhang P, Qiang S, Zhao Q, et al. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2. J Mol Cell Cardiol. 2018 Apr;117:26-35. 209. Ackerman MJ, Priori SG, Dubin AM, Kowey P, Linker NJ, Slotwiner D, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41-e44. 210. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on PracticeGuidelines. J AmColl Cardiol. 2014;63(22):2438-88. Erratum in: J Am Coll Cardiol. 2014;63(22):2489. 211. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55(25):2789-800. 212. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al; CURRENT AS Registry Investigators. Sudden death in patients with severe aortic stenosis: observations from the CURRENT AS registry. J Am Heart Assoc. 2018;7(11). pii: e008397. 213. Kanwar A, Thaden JJ, Nkomo VT. Management of patients with aortic valve stenosis. Mayo Clin Proc. 2018;93(4):488-508. 214. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349(11):1064-75. 215. Tarasoutchi F, MonteraMW, Ramos AI, Sampaio RO, Rosa VE, Accorsi TA, et al. Atualização das Diretrizes Brasileiras de Valvopatias: Abordagem das Lesões Anatomicamente Importantes. Arq Bras Cardiol. 2017;109(6 Supl. 2):1-34. 216. Baumgartner H, Otto CM. Aortic stenosis severity: do we need a new concept? J Am Coll Cardiol. 2009;54(11):1012-3. 217. Mantini C, Di Giammarco G, Pizzicannella J, Gallina S, Ricci F, D'Ugo E, et al.Gradingofaorticstenosisseverity:ahead-to-headcomparisonbetween cardiacmagnetic resonance imaging and echocardiography. Radiol Med. 2018;123(9):643-54. 218. Saeed S, Rajani R, Seifert R, Parkin D, Chambers JB. Exercise testing in patients with asymptomatic moderate or severe aortic stenosis. Heart. 2018 Apr 13. [Epub ahead of print]. 219. Nadeau-Routhier C, Marsit O, Beaudoin J. Current management of patients with severe aortic regurgitation. Curr Treat Options Cardiovasc Med. 2017;19(2):9. 220. Zoghbi WA, Enriquez-SaranoM, Foster E, Grayburn PA, Kraft CD, Levine RA, et al; American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with twodimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777-802. 221. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori L, et al. Prospective of valve regurgitation quantitation by cardiacmagnetic resonance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging. 2013;6(1):48-57. 222. Gabriel RS, Renapurkar R, Bolen MA, Verhaert D, Leiber M, Flamm SD, et al. Comparison of severity of aortic regurgitation by cardiovascular magnetic resonance versus transthoracic echocardiography. Am J Cardiol. 2011;108(7):1014-20. 223. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med. 1999;130(1):23-31. 224. Pelliccia A, Kinoshita N, Pisicchio C, Quattrini F, Dipaolo FM, Ciardo R, et al. Long-termclinical consequences of intense, uninterrupted endurance training in Olympic athletes. J Am Coll Cardiol. 2010;55(15):1619-25. 225. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete’s heart in women: echocardiographic characterization of highly trained elite female athletes. JAMA. 1996;276(3):211-5. 226. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical practice: a long-term follow-up study. Circulation. 1999;99(14):1851-7. 227. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation. 1991;84(4):1625-35. 228. Yoon SH, Maeno Y, Kawamori H, Miyasaka M, Nomura T, Ochiai T, et al. Diagnosis and outcomes of transcatheter aortic valve implantation in bicuspid aortic valve stenosis. Interv Cardiol. 2018;13(2):62-5. 229. Martín M, Lorca R, Rozado J, Alvarez-Cabo R, Calvo J, Pascual I, et al. Bicuspid aortic valve syndrome: a multidisciplinary approach for a complex entity. J Thorac Dis. 2017;9(Suppl 6):S454-S464. 230. SvenssonLG,KimKH,LytleBW,CosgroveDM.Relationshipofaorticcross- sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves. J Thorac Cardiovasc Surg. 2003;126(3):892-3. 231. Parker MW, Thompson PD. Exercise in valvular heart disease: risks and benefits. Prog Cardiovasc Dis. 2011;53(6):437-46. 232. Harb SC, Griffin BP. Mitral valve disease: a comprehensive review. Curr Cardiol Rep. 2017;19(8):73. 233. Rahimtoola SH, Durairaj A, Mehra A, Nuno I. Current evaluation and management of patients with mitral stenosis. Circulation. 2002;106(10):1183-8. 234. Sandoval Y, Sorajja P, Harris KM. Contemporarymanagement of ischemic mitral regurgitation: a review. Am J Med. 2018;131(8):887-95. 235. Bonow RO. Chronic mitral regurgitation and aortic regurgitation: have indications for surgery changed? J AmColl Cardiol. 2013;61(7):693-701. 236. Parwani P, Avierinos JF, Levine RA, Delling FN. Mitral valve prolapse: multimodality imaging and genetic insights. Prog Cardiovasc Dis. 2017;60(3):361-9. 237. Thacoor A. Mitral valve prolapse and Marfan syndrome. Congenit Heart Dis. 2017;12(4):430-4. 238. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1-7. 239. Narayanan K, Uy-Evanado A, Teodorescu C, Reinier K, Nichols GA, Gunson K, et al. Mitral valve prolapse and sudden cardiac arrest in the community. Heart Rhythm. 2016;13(2):498-503. 240. Delling FN, Rong J, Larson MG, Lehman B, Fuller D, Osypiuk E, et al. Evolution of mitral valve prolapse: insights from the Framingham heart study. Circulation. 2016;133(17):1688-95. 241. Basso C, PerazzoloMarraM, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, et al.Arrhythmicmitralvalveprolapseandsuddencardiacdeath.Circulation. 2015;132(7):556-66. 366